Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Lung cancer肺癌

ICD-10: C34 — Malignant neoplasm of bronchus and lung

Group: Cancer Specialty: Respiratory Medicine, Thoracic Surgery

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
肺癌
English name
Malignant neoplasm of bronchus and lung

Values written in Chinese are quoted as published by the source.

Also known as

  • NSCLC
  • SCLC

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 52000 – 81790 CNY Condition package price 病种打包全包价 2020–2025
Radiotherapy 放疗 19000 – 58000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 6550 – 9500 CNY Condition package price 病种打包全包价 2020–2021
Targeted therapy 靶向 20000 – 60000 CNY Per-item price 项目价 2024–2025
Immunotherapy 免疫 32043 – 43803 CNY Per-item price 项目价 2024–2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 81790 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 28.7% 95% CI 28.6–28.9

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published by stage (the source publishes the overall figure only)

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    3 more published studies

    PubMed indexes 5 papers on this condition that name this hospital.

    Also ranked: Medical Oncology #1, Urology nominated in the Fudan list.

  2. First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院

    Guangzhou 广州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    4 more published studies

    PubMed indexes 6 papers on this condition that name this hospital.

    Also ranked: Urology nominated in the Fudan list.

  3. Shanghai Chest Hospital上海市胸科医院（暨上海交通大学医学院附属胸科医院）

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    3 more published studies

    PubMed indexes 5 papers on this condition that name this hospital.

  4. China-Japan Friendship Hospital中日友好医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    2 more published studies

    PubMed indexes 4 papers on this condition that name this hospital.

  5. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #3, Urology #2 (tied), Otorhinolaryngology #8 in the Fudan list.

  6. Shanghai Pulmonary Hospital上海市肺科医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    11 more published studies

    PubMed indexes 13 papers on this condition that name this hospital.

  7. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Also ranked: General Surgery #1, Urology #8, Gynecology #1 in the Fudan list.

  8. Ruijin Hospital上海交通大学医学院附属瑞金医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

    Also ranked: General Surgery #4, Infectious Diseases 传染感染 #6, Nuclear Medicine 核医学 #10 in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Lung cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07182682

  2. Study Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection

    Hospital
    The Second Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06492421

  3. Study A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT07739758

  4. Study Efficacy and Safety of Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy as Neoadjuvant Treatment for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prospective Phase II Clinical Trial

    Lead investigator
    Hu Liao · Deputy Director & Medical Team Leader, Department of Thoracic Surgery, West China Hospital, Sichuan University; Associate Professor of Surgery; Master's Supervisor
    Hospital
    The Third People's Hospital of Chengdu
    Status
    Recruiting
    Registry
    NCT07855965

  5. Study A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer

    Hospital
    Peking University Shenzhen Hospital
    Status
    Recruiting
    Registry
    NCT07744256
116 more registered studies

  1. Study A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Hospital
    The First Affiliated Hospital of Nanchang University
    Status
    Recruiting
    Registry
    NCT06793215

  2. Study A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

    Lead investigator
    Wei Zhou · Department Director
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07425795

  3. Study Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial

    Lead investigator
    HuaiLiu · Prof.
    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06840704

  4. Study A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Recruiting
    Registry
    NCT06417008

  5. Study A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT06903377

  6. Study A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial

    Lead investigator
    Xuwei Cai · Director
    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT07091305

  7. Study A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07444437

  8. Study Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial

    Lead investigator
    Peng Zhang · Director
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Recruiting
    Registry
    NCT06256237

  9. Study Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

    Lead investigator
    Peng Zhang · Professor
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Recruiting
    Registry
    NCT05965024

  10. Study Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer: a Prospective, Observational Study

    Lead investigator
    Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Recruiting
    Registry
    NCT07328945

  11. Study Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population

    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT07381829

  12. Study A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06734182

  13. Study A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07662395

  14. Study A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT07217301

  15. Study An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT06179069

  16. Study Comparison of Segmentectomy Versus Lobectomy for Early-stage Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field: A Prospective and Multi-center RCT Study

    Hospital
    Jiangsu Province Hospital
    Status
    Recruiting
    Registry
    NCT04944563

  17. Study PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT07144280

  18. Study DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07472517

  19. Study A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06801834

  20. Study A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05920356

  21. Study Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis

    Hospital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06023212

  22. Study A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06631989

  23. Study Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)

    Lead investigator
    Tingting Yuan · Attending physician
    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT07508852

  24. Study Effectiveness of Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study

    Lead investigator
    Liu Zhishun · professer，Chief Physician
    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT06926140

  25. Study TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial

    Hospital
    The Second Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT03778814

  26. Study Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery

    Lead investigator
    Hongxu Liu · professor
    Hospital
    Liaoning Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06109454

  27. Study Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

    Lead investigator
    HAN GUANG · Chief physician
    Hospital
    Hubei Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06032052

  28. Study ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07361497

  29. Study A Single Arm, Open Label, Dose-escalating, Prospective Phase I Clinical Trial Evaluating the Safety, Tolerability and Efficacy of TMT101 Injection Alone in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) After Standard Treatment Failure

    Lead investigator
    Wu Wenming · Director, Chief Physician of Basic Surgery, Principal Investigator, Clinical Professor
    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT06861543

  30. Study A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT07143045

  31. Study Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial

    Lead investigator
    You Lu · Chair of Division of Thoracic Tumor Multimodality Treatment
    Hospital
    The Second Affiliated Hospital of Chongqing Medical University
    Status
    Recruiting
    Registry
    NCT06121505

  32. Study Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07677787

  33. Study Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT07416474

  34. Study A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of Almonertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based Chemoradiation Therapy

    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04951635

  35. Study The Therapeutic Effect of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Platinum Sensitive Recurrent Small Cell Lung Cancer

    Status
    Recruiting
    Registry
    NCT06467786

  36. Study A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07622186

  37. Study Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07775820

  38. Study Tubeless Anesthesia in Preventing Contralateral Lung Complications in Patients Undergoing Single-Port Thoracoscopic Surgery for Early-Stage Lung Cancer: A Single-Center, Prospective, Open-Label, Randomized Controlled Trial

    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT07024433

  39. Study Effectiveness of Perioperative Percutaneous Acupoint Acupuncture on Postoperative Sleep Disturbances in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial

    Lead investigator
    LIna Huang · Chief Physician, Department of Anesthesiology, Shanghai First People's Hospital
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT07662733

  40. Study Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer

    Lead investigator
    Cai Xiaoyue · Associate Chief Physician
    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT07515027

  41. Study Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients With Chinese Advanced Non-small Cell Lung Cancer

    Lead investigator
    Xiaomin Niu · Principal Investigator
    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT04977791

  42. Study Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform

    Lead investigator
    Xinghua Cheng · Director, Head of Oncology Surgery, Clinical Professor
    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT06483295

  43. Study The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

    Lead investigator
    Xuewen Liu · Professor
    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07138755

  44. Study A Phase I Clinical Study to Explore the Safety and Efficacy of Hypervision Proton Surgery (HyPROS) for Early-stage Non-small Cell Lung Cancer

    Lead investigator
    Shuanghu Yuan · Professor
    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT07195084

  45. Study A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07010263

  46. Study Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery

    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT07439991

  47. Study An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05099172

  48. Study Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.

    Lead investigator
    Rong Yu, MD · Investigator Official Title
    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06768307

  49. Study A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06312137

  50. Study Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) for CEA Positive Advanced Lung Cancer

    Status
    Recruiting
    Registry
    NCT06992583

  51. Study Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer

    Lead investigator
    Peng Zhang · Director of science and education department
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Recruiting
    Registry
    NCT04539977

  52. Study Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment (NAT-LungMate)

    Lead investigator
    Peng Zhang · Professor
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Recruiting
    Registry
    NCT05857800

  53. Study Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07806604

  54. Study The Shengjing Lung Cancer Cohort (SJ-LCC) Study

    Lead investigator
    Huanhuan Chen · Shengjing Hospital of China Medical University
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT07779005

  55. Study A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer

    Lead investigator
    Hui Liu · Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT07103395

  56. Study LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics

    Lead investigator
    Jianxing He · Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06778512

  57. Study An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06706713

  58. Study Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA): a Prospective Randomized Controlled Clinical Trial

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06215326

  59. Study Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07486817

  60. Study A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

    Lead investigator
    Xingwen Fan · associate professor
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT06943235

  61. Study Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

    Lead investigator
    Yang Fan, MD · Vice President
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT07359040

  62. Study A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.

    Hospital
    Cancer Hospital of Chinese Academy of Medical Sciences
    Status
    Recruiting
    Registry
    NCT05913089

  63. Study A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

    Hospital
    China-Japan Friendship Hospital
    Status
    Recruiting
    Registry
    NCT06203210

  64. Study Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT06950697

  65. Study Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

    Lead investigator
    Guangying Zhu · Clinical Professor, Chief Physician
    Hospital
    China-Japan Friendship Hospital
    Status
    Recruiting
    Registry
    NCT06692972

  66. Study A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT06858813

  67. Study Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)

    Lead investigator
    Fang Wu · Professor
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT05477979

  68. Study Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

    Lead investigator
    Fang Wu · Chief Physician, Associate Professor
    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT05979818

  69. Study The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging

    Lead investigator
    Fang Wu · Professor
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06975384

  70. Study Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes

    Lead investigator
    Chen Chen · Associate Professor
    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06699979

  71. Study A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07412262

  72. Study A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06899126

  73. Study Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT07059923

  74. Study Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06500312

  75. Study A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05956587

  76. Study The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial

    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06623487

  77. Study A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT06564324

  78. Study Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial

    Lead investigator
    Dong-Xin Wang · Chairman, Department of Anaesthesiology and Critical Care Medicine
    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT04209218

  79. Study A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

    Hospital
    First Affiliated Hospital of Xiamen University
    Status
    Not yet recruiting
    Registry
    NCT07031154

  80. Study Exploratory Clinical Study on Microwave Ablation With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

    Lead investigator
    Jiayuan Sun · Chief Physician
    Hospital
    Shanghai Chest Hospital
    Status
    Not yet recruiting
    Registry
    NCT06969781

  81. Study Efficacy and Safety of Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer: A Single-Center, Prospective, Single-Arm Clinical Trial

    Lead investigator
    Junfeng Geng · Professor
    Hospital
    Shanghai Chest Hospital
    Status
    Not yet recruiting
    Registry
    NCT07780591

  82. Study An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

    Hospital
    The First Hospital of Jilin University
    Status
    Not yet recruiting
    Registry
    NCT05784974

  83. Study Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study

    Lead investigator
    Wu Nan · Professor
    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06780839

  84. Study Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

    Lead investigator
    Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Not yet recruiting
    Registry
    NCT06620822

  85. Study A Multicenter Randomized Controlled Trial of an Intelligent Pulmonary Function Exercise Device Versus Usual Care for In-Hospital and Home-Based Pulmonary Rehabilitation After Lung Cancer Surgery

    Lead investigator
    Jianxing He · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07631520

  86. Study A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer

    Lead investigator
    Jianxing He · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07078032

  87. Study A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

    Lead investigator
    Jianxing He · Director, Head of Thoracic Surgery, Principal Investigator, Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07303881

  88. Study Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07170046

  89. Study Development of a Chest CT-Based Artificial Intelligence Model Across the Lung Cancer Care Continuum and a Prospective Randomized Crossover Reader Study of Its Clinical Decision-Support Performance

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT07829640

  90. Study A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Not yet recruiting
    Registry
    NCT07739199

  91. Study The Effects of Acupuncture for Lung Cancer-Related Fatigue, a Clinical Trial

    Lead investigator
    Yuanjie Sun · Doctor
    Hospital
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Status
    Not yet recruiting
    Registry
    NCT07079072

  92. Study Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study

    Hospital
    Ningbo No.2 Hospital
    Status
    Not yet recruiting
    Registry
    NCT06221462

  93. Study A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT05990127

  94. Study Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer

    Lead investigator
    Jiayuan Sun · Director, Department of Respiratory Endoscopy
    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Not yet recruiting
    Registry
    NCT06580665

  95. Study Organoid-Based Drug Sensitivity Model Guided Personalized Precision Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Hospital
    Peking Union Medical College Hospital
    Status
    Not yet recruiting
    Registry
    NCT07106528

  96. Study A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT05767892

  97. Study Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06236997

  98. Study An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

    Lead investigator
    Qiming Wang · Professor
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06454890

  99. Study Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

    Lead investigator
    Liu Fang · Director
    Hospital
    Third Affiliated Hospital of Harbin Medical University
    Status
    Not yet recruiting
    Registry
    NCT07398560

  100. Study Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

    Lead investigator
    Zhang Zhi · Associate Professor
    Hospital
    Jiangsu Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07286942

  101. Study Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

    Lead investigator
    Ji Yongling · PI
    Hospital
    Zhejiang Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07035860

  102. Study A Prospective, Multicenter, Randomized Controlled Clinical Trial Comparing Bronchoscopic Thermal Vapor Ablation and Percutaneous Microwave Ablation in Patients With COPD and Early-Stage Lung Cancer: Efficacy and Safety Evaluation

    Hospital
    Henan Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT06929390

  103. Study Effects of Different Preoperative Oral Rehydration Protocols on Safety, Comfort, and Postoperative Outcomes in Elderly Patients Undergoing Thoracoscopic Radical Lung Cancer Surgery: A Randomized Controlled Trial

    Hospital
    Fujian Medical University Union Hospital
    Status
    Not yet recruiting
    Registry
    NCT07042503

  104. Study The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes

    Lead investigator
    Liang Zhao · Dr
    Hospital
    Shanghai Chest Hospital
    Status
    Not yet recruiting
    Registry
    NCT07272057

  105. Study Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT06015568

  106. Study A Single-Arm Phase II Study of Intrathecal Thiotepa Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Not yet recruiting
    Registry
    NCT07778940

  107. Study A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Status
    Not yet recruiting
    Registry
    NCT07485920

  108. Study A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

    Hospital
    The First Affiliated Hospital of Fujian Medical University
    Status
    Not yet recruiting
    Registry
    NCT07771764

  109. Study Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial

    Lead investigator
    Peng Zhang · associate professor of medicine
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Not yet recruiting
    Registry
    NCT05496166

  110. Study Furmonertinib Combined With Local Therapy in Inoperable or Surgery-Refusing Early-Stage Non-Small Cell Lung Cancer:A Single-arm, Phase II Study

    Lead investigator
    Xuefei Hu · Chief Physician
    Hospital
    Shanghai Pulmonary Hospital
    Status
    Not yet recruiting
    Registry
    NCT07517640

  111. Study A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer

    Hospital
    Shanghai Pulmonary Hospital
    Status
    Not yet recruiting
    Registry
    NCT07704645

  112. Study An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients

    Lead investigator
    Yalei Zhang · The First Affiliated Hospital of Guangzhou Medical University
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07142057

  113. Study Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

    Lead investigator
    Jianxing He · Chief physician
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT06893354

  114. Study Phase II, Open-label, Single-arm, Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Lorlatinib as Neoadjuvant Treatment in Surgically Resectable Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)

    Lead investigator
    Yang Fan, MD · Professor of Thoracic Surgery
    Hospital
    Peking University People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT06682884

  115. Study The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial

    Lead investigator
    Gang Hou · Professor
    Hospital
    China-Japan Friendship Hospital
    Status
    Not yet recruiting
    Registry
    NCT06739421

  116. Study A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Not yet recruiting
    Registry
    NCT06885840

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 46 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Ruijin Hospital上海交通大学医学院附属瑞金医院 Shanghai 上海市 Respiratory Medicine 呼吸内科 Level B https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Shanghai General Hospital上海市第一人民医院 Shanghai 上海市 Respiratory Medicine 呼吸科 Level B https://www.firsthospital.cn/List/Depart/f0
Shanghai Pulmonary Hospital上海市肺科医院 Shanghai 上海市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Shanghai Chest Hospital上海市胸科医院（暨上海交通大学医学院附属胸科医院） Shanghai 上海市 Thoracic Surgery 胸外科专业 Level B https://www.shxkyy.com/hz/list/190/1400.html
Zhongshan Hospital复旦大学附属中山医院 Shanghai 上海市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Respiratory Medicine 呼吸与危重症医学科 · Thoracic Surgery 胸外科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Beijing Hospital北京医院 Beijing 北京市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Respiratory Medicine 呼吸科 · Thoracic Surgery 胸外科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Respiratory Medicine 呼吸与危重症医学科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
Beijing Chao-Yang Hospital, Capital Medical University首都医科大学附属北京朝阳医院 Beijing 北京市 Respiratory Medicine 呼吸与危重症医学科 Level B https://www.bjcyh.com.cn/Html/News/Articles/21528.html
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital四川省医学科学院·四川省人民医院 Chengdu 成都市 Respiratory Medicine 呼吸内科 Level B https://www.samsph.com/introduce/
Tianjin Medical University General Hospital天津医科大学总医院 Tianjin 天津市 Respiratory Medicine 呼吸内科 Level B https://www.tjmugh.com.cn/system/2019/01/02/020008655.shtml
Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 Tianjin 天津市 Thoracic Surgery 胸外科 Level B https://www.tjmuch.com/yygk/yyjj/index_yg.shtml
The First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 Hefei 合肥市 Respiratory Medicine 呼吸内科 Level B https://www.ayfy.com/info/1184/27750.htm
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Qianfoshan Hospital山东省千佛山医院 Jinan 济南市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://sysucc.org.cn/department/introduction/41
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Nanfang Hospital南方医科大学南方医院 Guangzhou 广州市 Respiratory Medicine 呼吸与危重症医学科 Level A https://portal.smu.edu.cn/yzw/info/1023/11291.htm
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://static.nfnews.com/content/202503/22/c11108498.html
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 Guangzhou 广州市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Jiangsu Province Hospital江苏省人民医院（南京医科大学第一附属医院） Nanjing 南京市 Respiratory Medicine 呼吸与危重症医学科 Level B https://www.jsph.org.cn/ksjj/ksjs/nk1/hxywzzyxk.htm
Jiangsu Cancer Hospital江苏省肿瘤医院 Nanjing 南京市 Thoracic Surgery 胸外科 Level B https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Henan Provincial People's Hospital河南省人民医院 Zhengzhou 郑州市 Respiratory Medicine 呼吸与危重症医学科 Level B https://www.hnsrmyy.net/jzzn/ksdh/nk/hxywzzyxk/ksjj.htm
Henan Cancer Hospital河南省肿瘤医院 Zhengzhou 郑州市 Thoracic Surgery 胸外科 Level B https://www.anti-cancer.com.cn/Html/News/Articles/13202.html
First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院 Zhengzhou 郑州市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B Level C https://www.zdyfy.cn/tsyl/gjjlczdzk
Not published
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院 Hangzhou 杭州市 Respiratory Medicine 呼吸内科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
The Second Affiliated Hospital Zhejiang University School of Medicine浙江大学医学院附属第二医院 Hangzhou 杭州市 Respiratory Medicine 呼吸内科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine浙江大学医学院附属邵逸夫医院 Hangzhou 杭州市 Respiratory Medicine 呼吸与危重症医学科 Level B https://www.srrsh.com/sywhInfo/536
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Respiratory Medicine 呼吸与危重症医学科 · Thoracic Surgery 胸外科 Level B https://www.whuh.com/kxyj/xkjs/gjlczdzk.htm
https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.tjh.com.cn/contents/934/27291.html
Renmin Hospital of Wuhan University武汉大学人民医院 Wuhan 武汉市 Thoracic Surgery 胸外科 Level B https://www.rmhospital.com/article/id/16939.html
Third Xiangya Hospital中南大学湘雅三医院 Changsha 长沙市 Respiratory Medicine 呼吸与危重症医学科（培育项目） Level B https://www.xy3yy.com/ksjj/184173.html
Second Xiangya Hospital of Central South University中南大学湘雅二医院 Changsha 长沙市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.xyeyy.com/655/656/664/
Xiangya Hospital of Central South University中南大学湘雅医院 Changsha 长沙市 Respiratory Medicine 呼吸内科 Level B https://www.xiangya.com.cn/zdzk.html
Shengjing Hospital中国医科大学附属盛京医院 Shenyang 沈阳市 Respiratory Medicine 呼吸科 · Thoracic Surgery 胸外科 Level B https://www.sj-hospital.cn/article/2816.html
https://www.sj-hospital.org/sjweekly/resfile/2024-01-26/16/sjzk-20240126-016.pdf
First Hospital of China Medical University中国医科大学附属第一医院 Shenyang 沈阳市 Respiratory Medicine 呼吸与危重症医学科（呼吸系病） · Thoracic Surgery 胸外科 Level A Level B https://www.cmu1h.com/features/specialty
https://wsjk.ln.gov.cn/wsjk/index/gsgg/D6FB5218203A456D9540155A2D928D84/index.shtml
Liaoning Cancer Hospital辽宁省肿瘤医院 Shenyang 沈阳市 Thoracic Surgery 胸外科 Level B https://www.lnchi.org.cn/ch/hospital/biref/index.html
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
The Second Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院 Chongqing 重庆市 Respiratory Medicine 呼吸内科 Level B https://www.cqsahcqmu.cn/mobile/index.php?c=category&id=1013
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院 Xi'an 西安市 Respiratory Medicine 呼吸内科 · Thoracic Surgery 胸外科 Level B https://news.xjtu.edu.cn/info/1033/17951.htm
http://www.dyyy.xjtu.edu.cn/info/41461/122341.htm
The Second Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院 Xi'an 西安市 Respiratory Medicine 呼吸内科 Level B https://news.xjtu.edu.cn/info/1219/169067.htm
Shaanxi Provincial People's Hospital陕西省人民医院 Xi'an 西安市 Respiratory Medicine 呼吸内科 Level B https://www.spph-sx.com/zlfw1/zdzk.htm

46 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 7 ICD codes
Version Code Name in that version
ICD-10-WHO C34 Malignant neoplasm of bronchus and lung
ICD-10-WHO C34.0 Main bronchus
ICD-10-WHO C34.1 Upper lobe, bronchus or lung
ICD-10-WHO C34.2 Middle lobe, bronchus or lung
ICD-10-WHO C34.3 Lower lobe, bronchus or lung
ICD-10-WHO C34.8 Overlapping lesion of bronchus and lung
ICD-10-WHO C34.9 Bronchus or lung, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24